Links for Keyword: ALS-Lou Gehrig's Disease
Follow us on Facebook and Twitter, or subscribe to our mailing list, to receive news updates. Learn more.
By Devin Powell Even with the entire human genome in hand, scientists can still have trouble rooting out the genes behind a disease. Consider amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. One ALS-related gene mutation was found in 1993, but it affects only 1% of all ALS patients. Now, after a long dry spell, researchers have finally hit on a second. It's just as rare as the first, but it seems to be more closely related to aspects of ALS pathology found in all patients. ALS typically appears in middle age, slowly destroying the motor neurons used to control muscles and usually killing a patient within 5 years of diagnosis. Five percent of all adult-onset ALS cases are known to have a strong genetic component, affecting multiple family members. But the rest seem to appear spontaneously in people with no prior family history. Scientists know little about what causes these sporadic cases. And the one known ALS gene in inherited ALS, called SOD1, doesn't seem to lead to neuronal death--the primary characteristic of ALS--so the link between this gene and the disease is still unclear. Christopher Shaw, a neurologist at King's College London, started hunting for other ALS genes by recruiting patients who have the inherited form of the disease but not the SOD1 mutation. While screening 154 people with familial ALS, Shaw and his colleagues found four individuals in one family who shared the same mutation: a single changed base on chromosome 1. The base was located in the TDPB gene, which encodes a protein called TDP-43 whose function isn't clear. In 2006, scientists reported that in both inherited and sporadic ALS, this protein disappears from the nucleus and clumps up in the cytoplasm of brain and motor neurons. © 2008 American Association for the Advancement of Science.
A rigorous study in Italy has confirmed claims that professional soccer players have a higher than normal risk of developing a type of motor neuron disease, also known as amyotrophic lateral sclerosis. The reason remains a mystery. ALS involves the death of motor neurons, the nerve cells responsible for voluntary movement, and eventually leads to paralysis and death. Adriano Chiņ's team at the University of Turin surveyed the medical records of 7000 professional footballers who played in Italy's first or second division between 1970 and 2001. Based on the normal incidence of the disease and the players' ages, the researchers calculated that there should have been 0.8 cases of ALS in this group. Instead, there were five. The study was prompted by what the Italian press dubbed "the motor neuron mystery" - the discovery a few years ago of 33 cases of ALS during an investigation of illicit drug use among 24,000 pro and semi-pro players in Italy. Dubious about the methodology of that initial investigation, Chiņ's group applied stricter diagnostic criteria to their data, such as only including players born in Italy. "I think the researchers have been conservative," says Ammar Al-Chalabi of the Institute of Psychiatry in London, who has written a commentary on the study in Brain. © Copyright Reed Business Information Ltd.
By Jennifer Warner -- Despite the famous link between ALS and baseball great Lou Gehrig, a new study shows that there's no medical link between the disease and physical activity. Researchers found no association between increased physical activity and the risk of developing ALS (amyotrophic lateral sclerosis). Those results contradict several previous studies that have shown that slim, athletic individuals may be more likely to develop ALS. ALS is also sometimes called "Lou Gehrig's disease," after the famous baseball player whose career was cut short by the disease, which gradually erodes muscle strength. Although ALS is often very disabling, many people live for years with the disease. The average life expectancy is only two to five years. In the study, researchers compared the amount of physical activity reported by 219 people with ALS with 254 healthy people. All of the participants were asked whether they engaged in sports as youngsters or as an adult or whether they performed extreme physical activity. They reported total physical activity levels as well as activity levels in three different phases of their lives: before age 25, the last 10 years before symptoms of the disease emerged, and one year before the start of the disease. ©1996-2005 WebMD Inc.
Carl T. Hall, Chronicle Science Writer Dr. Richard Olney, a San Francisco neurologist and pioneer in ALS research, has launched an ambitious clinical trial testing whether two established drugs used in AIDS and cancer might also help some ALS patients. It's a trial that Olney designed and expected to lead as head of a specialized clinic at UCSF for people with ALS, or amyotrophic lateral sclerosis, popularly known as Lou Gehrig's disease. Those plans have changed. For this trial, Olney is participating not as a doctor, but as one of 60 patients. In fact, he made it a point to be the first one to sign up. He went through the initial round of evaluations last week. He expects to be given either the AIDS drug, a protease inhibitor called ritonavir; or the cancer drug, hydroxyurea; or a placebo, starting in about two weeks. Olney, 56, is regarded to be among the country's top clinical investigators of ALS, having spent most of his career conducting trials and working with patients. In June, he was diagnosed with the same disease he has spent a lifetime studying. It's a twist of fate that has shocked the close-knit ALS world. The case also underscores the challenges posed by one of the deadliest -- and fastest- moving -- disorders of the nervous system. ©2005 San Francisco Chronicle
Carl T. Hall, Chronicle Science Writer Dr. Richard Olney first got interested in the neuromuscular disease known as amyotrophic lateral sclerosis, or ALS, when the daughter of his favorite teacher in junior high school died of it. He soon came to regard ALS, also known as Lou Gehrig's disease, as one of the most compelling -- and justly feared -- disorders of the nervous system. And so, during 25 years as a neurologist, Olney devoted his career to the care of ALS patients, founding a specialized clinic at UCSF. He resigned as clinic director this summer and has stopped treating all his patients with ALS. But he has even more reason these days to be interested in their disease. Now, it is his disease. In June, Olney, 56, regarded as one of the top ALS clinicians in the country, was diagnosed with ALS. ALS is not contagious. He didn't catch it from close contact with a patient. It's just a matter of unhappy fortune -- just one more case in one of the biggest ongoing mysteries of brain research. ©2004 San Francisco Chronicle
Michael Hopkin The British scientist who created Dolly the sheep has applied for a licence to clone human embryos in the search for treatments for motor neuron disease. If approved, the research should give experts a far better picture of what happens to the dying brain cells that characterize this condition. Ian Wilmut, of the Roslin Institute in Edinburgh, and his colleagues submitted their proposal today to the UK Human Fertilisation and Embryology Authority (HFEA). They hope to receive a decision early next year and could potentially begin cloning around April 2005. Motor neuron disease, a range of related conditions including amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, causes around 1,000 deaths in Britain every year. The brain cells that govern movement gradually die off, leaving sufferers paralysed but, usually, with their intellect intact. The causes are still poorly understood, says Wilmut. Around 2% of cases are linked to mutations in a gene called SOD1, although experts are still unclear about how this triggers disease. And a further 8% of patients inherit their disease and therefore presumably have some other genetic predisposition. ©2004 Nature Publishing Group
Related chapters from BP7e: Chapter 11: Motor Control and Plasticity; Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 5: The Sensorimotor System; Chapter 13: Memory, Learning, and Development
Link ID: 6166 - Posted: 06.24.2010
Chemical cause sought for damage to soldiers' nerves. EMILY SINGER Men who have served in the US military are 60% more likely to develop a fatal muscle-wasting disease than civilians, research suggests. The study hints that all military personnel are at increased risk, not just those who served in the first Gulf War. The nerve disorder, known as amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease, is a relatively rare disease that causes nerve-cell death and muscle wasting. Studies have suggested that the risk of ALS is raised among Gulf War veterans. So Marc Weisskopf from the Harvard School of Public Health, Boston, and colleagues decided to see if military service in other conflicts had a similar effect. The researchers studied the causes of death of around 400,000 men over a nine-year period. Some 217 veterans developed ALS compared with just 63 civilians, researchers revealed at the American Academy of Neurology meeting in San Francisco this week. © Nature News Service / Macmillan Magazines Ltd 2004
By Carol Cruzan Morton, Globe Correspondent More than 50 years ago, US Navy doctors stationed on the Pacific island of Guam found a shocking rate of an unknown neurodegenerative disease with the fatal progressive paralysis of Lou Gehrig's disease, the tremors of Parkinson's, and the forgetfulness of dementia. Guam's indigenous Chamorro people were 50 times to 100 times more likely to suffer the symptoms of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease and ALS, than populations just about anyplace else on the planet. In one village, more than a quarter of the adults who died between 1944 and 1953 were the victims of this mysterious combination of brain illnesses. Hundreds of research papers since have investigated and dismissed a variety of suspected causes, including microbes, genes, mineral deficiencies and nerve toxins. © Copyright 2003 Globe Newspaper Company.
Veterans of the 1991 Persian Gulf War may be more than twice as likely to be stricken with Lou Gehrig's disease than members of the general population are, new findings suggest. What is more, the condition often strikes vets sooner than those who did not serve, according to the results of two studies published in the current issue of the journal Neurology. Some soldiers who completed tours of duty during the first Gulf conflict complained of ill health after their return home. Gulf War syndrome, which lists fatigue, joint pain, depression, balance problems and diarrhea among its symptoms, was first diagnosed in 1997 and is said to be linked to exposure to toxic chemicals. That same year, Robert Haley of the University of Texas Southwestern Medical Center began investigating a potential connection between time served in the Persian Gulf and Lou Gehrig's disease--amyotrophic lateral sclerosis (ALS)--after receiving a request from a 35-year-old veteran suffering from the fatal affliction. The researchers located 17 veterans under the age of 45 who were diagnosed with ALS between 1991 and 1998. Of these individuals, five were diagnosed in 1998--in contrast to the 1.38 cases expected for an age group of this size. "The increasing slope of the epidemic curve beginning three years after the Gulf War and still increasing in 1998 further supports a true excess. © 1996-2003 Scientific American, Inc. All rights reserved.
Nathan Seppa Scientists' best efforts have failed to vanquish amyotrophic lateral sclerosis (ALS). There was no cure for the nerve-degenerating disease when it struck down baseball star Lou Gehrig 64 years ago, and there is none today. In fact, scientists have yet to pinpoint a cause of the disease except in individuals with certain rare genetic mutations. In the August Nature Genetics , researchers report on other, more common genetic variations that crop up in ALS patients more often than they do in healthy people. Experiments show that similar genetic variations leave mice vulnerable to the sort of nerve degeneration seen in ALS patients, says Peter Carmeliet of Leuven University in Belgium. He and his colleagues compared genetic profiles of 750 ALS patients with those of 1,219 healthy people of similar age in Belgium, Sweden, and Great Britain. The people with ALS were nearly twice as likely to have one of two variant forms of a gene for the protein called vascular endothelial growth factor (VEGF). Copyright ©2003 Science Service.
LeRoy Hunter says in his family, falling down was a serious concern By Tyler Vincent, The Journal-Standard FREEPORT - Growing up with a mother afflicted with amyotrophic lateral sclerosis, or Lou Gehrig's disease, is bound to have an effect on a young man's outlook on life. Certainly that was the case for Freeport resident LeRoy Hunter, who reflects on those memories in his home office, in front of his walker that he has used for the last two years. Hunter, who was diagnosed with ALS in 1995, will be appearing on the Rockford edition of the Jerry Lewis Labor Day Muscular Dystrophy Association Telethon, which began Sunday night and runs through Labor Day. Copyright © 1995 - 2002 PowerOne Media, Inc. All Rights Reserved.
Copyright © 2002 AP Online By MALCOLM RITTER, AP Science Writer An ordinary antibiotic slowed the progression of Lou Gehrig's disease in mice, suggesting a potential new approach for treating people, researchers report. The disease, formally known as amyotrophic lateral sclerosis or ALS, attacks nerve cells that control movement. As these cells degenerate, an affected person becomes progressively paralyzed. Most cases appear between the ages of 40 and 70, and death follows an average of four years after symptoms appear. The antibiotic, minocycline, was shown recently to prolong the lives of mice with a version of Huntington's disease, another neurodegenerative disorder. It is now being tested against Huntington's in people. Copyright © 2001 Nando Media
It is one of the most difficult diseases I deal with, without question, a neurologist says. By Kathleen O?Dell News-Leader The disease already had its deadly grip on respiratory therapist Jeff Taylor when the first symptom showed up: His right-hand grip was weak. Then his arm. Then his left hand; his left arm. Surgeon Mark Avery began slurring his speech; his tongue felt thick. By the time the Springfield men were diagnosed with ALS, amyotrophic lateral sclerosis, it was already too late. The disease gradually took away their strength, then their movement and, finally, their lives. ALS, also known as Lou Gehrigs disease, is a fatal disease that researchers are scrambling to understand even as the number of cases seem to be growing in Missouri and nationwide, said Kim Goble, with the Springfield ALS chapter. Part of that growth could stem from more accurate diagnoses, said Springfield neurologist Rodney Quinn. (There used to be something called 'creeping paralysis,' Goble observed.) Copyright © 2002, The Springfield News-Leader
By EMMA ROSS AP Medical Writer LONDON (AP)--Some of the world's leading scientists gathered Monday at Cambridge University to celebrate the 60th birthday of physicist Stephen Hawking, who has survived a remarkable 38 years with motor neuron disease. The university is staging a week of events to honor Hawking, concluding Friday with a symposium celebrating his contributions to fundamental physics and cosmology. His birthday is Tuesday. Hawking, a professor of mathematics at Cambridge and author of ``A Brief History of Time,'' was told he could not expect to live long when he was diagnosed at age 22 with amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. The average survival time is three to five years from the onset of symptoms. © 2002 Cox Interactive Media
NewScientist.com news service A cellular version of a traffic jam may be what causes neurodegenerative diseases like the one suffered by the astrophysicist Stephen Hawking. Using a genetically engineered mouse, researchers in Pennsylvania have shown that clogging up the routes between motor neurons and the muscles they control can be a cause, rather than a symptom, of lost motor control. Motor neurons reside in the brain and spinal cord but control movements in body parts as far away as our toes and fingers. To do this, they have very long projections, or axons, which sometimes stretch up to a metre in length. Good motor control depends on these axons acting as supply routes, to transport proteins and other molecules back and forth. © Copyright Reed Business Information Ltd.
By Brooke Adams The mice at the top of a column of stacked plastic bins at Q Therapeutics are shivering so hard they seem to be jumping. Their nonstop shivering and seizures are caused by a genetic defect that robs the mice of the crucial myelin sheath that surrounds nerve cells and helps them send signals. Because of the defect, the mice are soon paralyzed and die prematurely. It is a related problem -- loss of this myelin sheath -- that in humans causes the progressive loss of function in multiple sclerosis and several other diseases that can cause paralysis in humans. And that's why what has happened to the mice is so promising: After being treated with an adult stem cell therapy developed at Q Therapeutics, they are no longer shivering. The product, called Q-Cells, also may be applicable to such neurodegenerative diseases as Parkinson's, Alzheimer's and amyotrophic lateral sclerosis, or ALS -- better known as Lou Gehrig's disease. Now, the National Institutes of Health have awarded a $5 million grant to Q Therapeutics, the University of Utah's Cell Therapy Facility and Johns Hopkins University School of Medicine, which as a team has had success in animal models of ALS.
Scientists have identified a protective gene that increases survival in motor neuron disease. People with the KIFAP3 gene lived 14 months longer on average than other MND patients. Experts hope they will be able to use this knowledge to develop life-extending treatments for patients with this debilitating and fatal disease. So far, one drug, riluzole, has been proven to extend life expectancy, but only by a few months. MND attacks the nerves that control movement and is often rapidly progressive. The vast majority of people with MND die within two to five years. Half of people die within 14 months of diagnosis. The researchers wanted to find out why a small minority appear to be more resistant to the disease. To do this they looked at 300,000 genetic variants in 2,359 people with MND and 2,814 unaffected volunteers from six different countries. They found that people with two beneficial variants of KIFAP3 lived on average four years while those with only one or none lived on average for two years and eight months. This improved the chances of surviving five years from about 10% to more than 30% for those carrying the "good" variants of KIFAP3. Lead researcher Professor Ammar Al-Chalabi, of King's College London, said scientists would now be able to work on designing new treatments based on KIFAP3. Treatments can now be directly designed to exploit the effect of this gene variation." (C)BBC
A gene linked to a type of motor neurone disease that runs in families has been found after a 10-year search. Along with a related gene reported last year, it opens up an unexplored area of research into the condition, investigators said. The finding will also help doctors screen and counsel families at risk of the disease, the US and UK team wrote in Science. Up to 10% of cases are inherited within families because of genetic mutations. Motor neurone disease (MND) involves the progressive wasting of the muscles, while usually leaving the mind unaffected. It affects some 5,000 people in the UK. The first MND gene - SOD1 - was found in 1993 and it has been a major focus of research. But then researchers found a protein called TDP-43 is deposited in the neurons of 90% of people with the condition. However, it was not apparent in animal models with the SOD1 mutation, suggesting that the first gene found is not linked with the major underlying biology of the disease. For the past decade the UK and US team have been looking for a gene believed to be located on chromosome 16. They eventually found a mutation in the FUS gene in one family with inherited MND - also known as amyotrophic lateral sclerosis. Further studies showed that 4% of all families had FUS mutations. The FUS gene is related to TDP-43, the gene for which was found by the same researchers last year. Professor Christopher Shaw, from the Institute of Psychiatry at Kings College London, said the FUS gene was a very important clue as to what causes motor neurons to degenerate. "It's very interesting, we really have wrung SOD1 out. We have looked at cells and mice endlessly, but the major pathways are not SOD pathways. The genetic pieces of the jigsaw puzzle are beginning to fit together, leading us in new and exciting directions of research." (C)BBC
Scientists have identified a molecule which could be key to understanding the cause of motor neurone disease (MND) and other neurodegenerative disorders. The Proceedings of the National Academy of Sciences study raise the hope of new treatments being developed. The London-based team showed the molecule, Wnt3, plays a key role in establishing connections between nerve cells and the muscles they control. These connections become progressively weaker in MND patients. Without properly-formed connections - or synapses - the muscle cannot receive the nerve signal that tells it to contract. This results in the muscle weakness that is typical of MND. However, scientists have not been clear how synapses are formed in normal circumstances and this has made it very difficult to pin down what goes wrong in MND. The researchers, from University College London and King's College London, identified Wnt3 as key to the process. It assists a second molecule, called Agrin, which co-ordinates construction of the connection - or synapse. Lead researcher Professor Patricia Salinas said: "The work we are publishing today puts an important piece of the puzzle in place and offers up a new possibility for developing drugs to treat MND and other neurodegenerative diseases. "If we can build up a thorough picture to show how synapses are normally formed between nerves and muscles we can start to look for any elements that aren't working properly in people with MND. This might also lead to strategies for nerve repair after an injury." (C)BBC
By Adam Brimelow British scientists are embarking on a major new trial to assess the impact of the mood stabiliser lithium as a treatment for motor neurone disease. They say the research is necessary because positive findings from a small-scale Italian study were "too dramatic to ignore". But they are urging patients with the disease not to take the treatment in advance of their results. They warn that some side-effects of lithium are potentially dangerous. There are about 5,000 people in the UK living with motor neurone disease (MND). At the moment there is no effective cure or treatment. It is often rapidly progressive and always fatal, usually within two to five years. The disease can affect any adult at any age, although it is more commonly found in men, and is most likely to strike between the ages of 50 and 70. Lithium, a naturally occuring element, has long been used as a treatment for some forms of depression, such as bipolar disorder. But recent laboratory tests and animal trials have suggested that it may also have a protective effect with MND. The recent trial of 16 people in Italy reported encouraging results. But the MND Association said the study was small and poorly designed, and that its findings should be treated with caution. The association's president, Professor Sir Colin Blakemore, said: "If you read the publication optimistically it might be taken to mean that lithium literally cures this disease. "But it's very important, against the background of patient hopes and expectations, to stand back and ask whether the trial was large enough to make the claims that it did." (C)BBC
Related chapters from BP7e: Chapter 11: Motor Control and Plasticity; Chapter 16: Psychopathology: Biological Basis of Behavior Disorders
Related chapters from MM:Chapter 5: The Sensorimotor System; Chapter 12: Psychopathology: Biological Basis of Behavioral Disorders
Link ID: 12201 - Posted: 11.03.2008